Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO to Present at 10th Annual CNS Summit 2019

30 Oct 2019 09:00

RNS Number : 5364R
IXICO plc
30 October 2019
 

30 October 2019

 

IXICO plc

("IXICO" or the "Company")

 

IXICO to Present at 10th Annual CNS Summit 2019

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit 

31st October - 3rd November 2019, Boca Raton Resort, Florida, USA

 

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs. 

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

 

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

 

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus

 

IXICO@optimumcomms.com

 

 

About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

About CNS Summit

 

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABRBDGXXDBGCC
Date   Source Headline
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options
30th Jan 201710:28 amRNSResult of AGM
17th Jan 20174:09 pmRNSDirector/PDMR Shareholding
17th Jan 20177:00 amRNSAppointment of Giulio Cerroni as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.